|
⚲
|
| Keyboard |
| Superstring Capital Management LP
✚
|
|
|---|---|
| CRD # | 305743 |
| SEC # | 801-118766 |
| CIK # | 0001931118 |
| AUM | 339.5 M (2026-03-30) |
| Employees | 5 (60% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 212-257-5690 |
| Address | 150 E 52nd St New York, NY 10022 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($M) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/30/2026) [Brochure] |
|---|
Item 5 - Fees and Compensation Management Fees With respect to the Funds and SMA, Superstring predominantly receives Management Fees at an annual rate between 1.0%-2.0% (the “Management Fee”), depending on the particular share class of the Funds. The Management Fee is deducted from the Funds quarterly in advance and prorated for any investment period less than a full calendar quarter. The Management Fee is refundable if the advisory contract is cancelled prior to the end of a payment period. The Management Fees is described in more detail in the relevant Fund Documents. Superstring Capital Management, LP Form ADV Part 2A While the Management Fee is generally non-negotiable, Superstring may waive or modify the Management Fee for certain Investors that are members, employees or affiliates of Superstring, relatives of such persons, or for certain large or strategic Investors. Other Expenses The Funds bear their own expenses and generally are allocated a proportionate share of investment and operational expenses. These expenses may include, among other things: legal, administration, audit and accounting expenses (including third-party accounting services); proxy voting services; investment expenses such as commissions, research fees, market data and similar expenses; interest on margin accounts and other indebtedness; borrowing charges on securities sold short; custodial fees; bank service fees; Fund-related insurance costs (including D&O and E&O insurance for Superstring and the general partner); and any other expenses related to the purchase, sale, or transmittal of the Funds’ assets. The inclusion of an expense category in a Fund’s Fund Documents will not impose on Superstring an obligation to charge an expense (or the full amount of that expense) to that Fund; instead, permitted expenses will be allocated and charged in Superstring’s discretion to the Fund(s) it deems appropriate If Superstring incurs any of the above expenses on behalf of the Funds, then the Firm will allocate such expenses among the Funds in proportion to the size of the investment made in the activity by each Fund, to the entity to which the expense relates, or in such other manner as Superstring considers fair and reasonable. The Firm shall bear its own overhead costs or expenses, including, without limitation, the salaries and benefits of the Firm’s employees performing the services as described in the Fund Documents. For a more detailed discussion of brokerage and transaction costs, Investors are directed to |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/30/2026) [Brochure] |
|---|
Item 7 - Types of Clients The Firm provides discretionary advice to its Funds and SMA. The Fund Documents provide the eligibility criteria and minimum investment requirements. In general, each Investor in the Funds is a “qualified purchaser” as defined in Section 2(a)(51) of the Investment Company Act of 1940, as amended. Although Superstring has the authority to accept subscriptions of a lesser amount, the required minimum initial investment is generally US$5,000,000 for the Hedge Fund and US$1,000,000 for the PE Fund. Superstring also manages one separately managed account. |
| CIK | Period |
|---|---|
| 0001931118 |
| Sector | Form 13F Holdings | Value ($M) |
|---|---|---|
| Summit Therapeutics PLC | 16.9 | |
| Health Sciences Acquisitions Corp | 8.9 | |
| UNUM Therapeutics Inc | 8.7 | |
| Adventrx Pharmaceuticals Inc | 8.7 | |
| UroGen Pharma Ltd | 7.0 | |
| MIND Medicine Mindmed Inc | 6.6 | |
| VIR Biotechnology Inc | 6.5 | |
| Vaxcyte Inc | 6.4 | |
| Celldex Therapeutics Inc | 5.7 | |
| Sionna Therapeutics Inc | 5.7 | |
| Genmab A/S | 5.3 | |
| Zai Lab Ltd | 5.2 | |
| Vertex Pharmaceuticals Inc / Ma | 4.9 | |
| Quintiles Transnational Holdings Inc | 4.4 | |
| Maplight Therapeutics Inc | 3.9 | |
| Arvinas Inc | 3.3 | |
| ARCA Biopharma Inc | 3.1 | |
| United Therapeutics Corp | 3.1 | |
| Desert Gateway Inc | 3.1 | |
| Trevi Therapeutics Inc | 3.0 | |
| Adlai Nortye Ltd | 2.9 | |
| Cabaletta Bio Inc | 2.9 | |
| Pfizer Inc | 2.1 | |
| Axsome Therapeutics Inc | 1.9 | |
| Oric Pharmaceuticals Inc | 1.5 | |
| Aclaris Therapeutics Inc | 1.4 | |
| Eliem Therapeutics Inc | 1.4 | |
| Taysha Gene Therapies Inc | 1.2 | |
| Bright Minds Biosciences Inc | 1.0 | |
| Tamandare Explorations Inc | 0.9 | Prev | Page 1 | Next |
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Superstring Private Opportunites Fund I LP | [2022-03-30] | 9.8 M | 34.4 M |
| Offered $100,000,000 · Filed 2021-06-14 (D) · Exemption 506(b), 3(c)(7) · Remaining $90,180,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| HF | Superstring Capital Master Fund LP | [2019-10-18] | 69.8 M | 281.3 M |
| Filed 2020-11-23 (D/A) · Exemption 506(b), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 5 | 315.7 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 1 | 23.8 |
| Total | 6 | 339.5 |
| By Discretionary | ||
| Discretionary | 6 | 339.5 |
| Non-Discretionary | 0 | 0.0 |
| Total | 6 | 339.5 |
| By Non-United States Persons | ||
| Non-United States Persons | 181.0 | |
| United States Persons | 158.5 | |
| Total | 6 | 339.5 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| George Song | Executive Officer | 6 | 2 | |
| Superstring Capital Management LP | Promoter | 4 | 2 | |
| Superstring Capital Fund GP LLC | Executive Officer | 3 | 2 | |
| Ting Guo | Executive Officer | 3 | 2 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001931118] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 5493000JPLGPU6IXS139 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Flight Deck Capital LP
✚
|
CA | 358.7 M |
|
Forager Capital Management LLC
✚
|
AL | 352.9 M |
|
Triatomic Management LP
✚
|
CA | 346.3 M |
|
Vedanta Management LP
✚
|
NY | 345.6 M |
|
Borderless Management LLC
✚
|
FL | 345.4 M |
|
North Run Capital LP
✚
|
MA | 334.5 M |
|
Opus Investment Management LLC
✚
|
NY | 331.9 M |
|
Wolf River Capital Management LLC
✚
|
TN | 328.7 M |
|
Gordonmd Global Investments LP
✚
|
CA | 322.3 M |
|
Talara Capital Management LLC
✚
|
NJ | 317.6 M |